Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy
Stergios A. Pοlyzos, Lampros Chrysavgis, Ilias D. Vachliotis, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 20-35
Closed Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
Ilias D. Vachliotis, Stergios A. Pοlyzos
Current Obesity Reports (2023) Vol. 12, Iss. 3, pp. 191-206
Open Access | Times Cited: 40
RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism
Xinyu Gu, Penghui Li, Xiaohui Gao, et al.
Oncogene (2024) Vol. 43, Iss. 9, pp. 624-635
Open Access | Times Cited: 12
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Yumin Wang, Joshua S. Fleishman, Tongda Li, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers
Alessandro Mantovani, Amedeo Lonardo, Norbert Stefan, et al.
Metabolism (2024) Vol. 160, pp. 156014-156014
Closed Access | Times Cited: 11
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17514-17514
Open Access | Times Cited: 21
The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: A systematic review and meta-analysis
Kai Pan, Jie Xu, Yuzhu Xu, et al.
Pharmacological Research (2024) Vol. 205, pp. 107251-107251
Open Access | Times Cited: 5
The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
Xiaoyan Li, Jie He, Qiuhua Sun
Clinical Nutrition (2024) Vol. 43, Iss. 9, pp. 2005-2016
Open Access | Times Cited: 5
Primary hepatic carcinosarcoma: a case report with insights from retrospective analysis of clinical characteristics and prognostic factors
Zonglei Zhao, Tao Wang, Zhexuan Sun, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021 to 2045
Chengxia Kan, Kexin Zhang, Yuqun Wang, et al.
Annals of Hepatology (2025), pp. 101898-101898
Open Access
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group.
Luis Antonio Díaz, Juan Pablo Arab, Francisco Idalsoaga, et al.
Annals of Hepatology (2025), pp. 101903-101903
Open Access
Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur
Stergios A. Pοlyzos, Christos S. Mantzoros
Metabolism (2025), pp. 156253-156253
Closed Access
Metabolic-associated fatty liver disease (MAFLD) promotes the progression of hepatocellular carcinoma by enhancing KIF20A expression
Xinsong Hu, Yifei Chen, Hao Ying, et al.
International Immunopharmacology (2025) Vol. 154, pp. 114589-114589
Closed Access
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
Carole Vitellius, Elvire Desjonqueres, Marie Lequoy, et al.
JHEP Reports (2024) Vol. 6, Iss. 10, pp. 101160-101160
Open Access | Times Cited: 4
Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis
Zeli Tang, Caibiao Wei, Xueling Deng, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications
Stavros P. Papadakos, Ioanna Ε. Stergiou, Nikolina Gkolemi, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3434-3434
Open Access | Times Cited: 9
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14704-14704
Open Access | Times Cited: 9
Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma
Yuan Ni, Maoqing Lu, Ming Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Trend analysis and age-period-cohort effects on morbidity and mortality of liver cancer from 2010 to 2020 in Guangzhou, China
Dedong Wang, Xiangzhi Hu, Huan Xu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight
Anqi Li, Rui Wang, Yu-Qiang Zhao, et al.
Metabolites (2024) Vol. 14, Iss. 6, pp. 325-325
Open Access | Times Cited: 3
Identification and analysis of significant genes in nonalcoholic steatohepatitis-hepatocellular carcinoma transformation: Bioinformatics analysis and machine learning approach
Qiyi Yu, Yidong Zhang, Jiaping Ni, et al.
Molecular Immunology (2024) Vol. 174, pp. 18-31
Closed Access | Times Cited: 3
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis
Jingyi Li, Bowen Yang, Zan Teng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Sonosensitizer Nanoplatforms Augmented Sonodynamic Therapy-Sensitizing Shikonin-Induced Necroptosis Against Hepatocellular Carcinoma
Huimin Tian, Haitao Shang, Yichi Chen, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7079-7092
Open Access | Times Cited: 8
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Lampros Chrysavgis, Spyridon Kazanas, Konstantina Bafa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3832-3832
Open Access | Times Cited: 2
Enhancing HepG2 cell apoptosis with a combined nanoparticle delivery of miR-128-3p agomir and Oroxin B: A novel drug delivery approach based on PI3K-AKT and VEGF pathway crosstalk
Hechen Wang, Xudan Shen, Xinlan Zhu, et al.
Asian Journal of Pharmaceutical Sciences (2024), pp. 100909-100909
Open Access | Times Cited: 2
Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin
Marica Meroni, Miriam Longo, Paola Dongiovanni
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top